FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.